Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (266) 266
Publication (24) 24
Patent (17) 17
Book / eBook (14) 14
Conference Proceeding (9) 9
Book Review (3) 3
Newspaper Article (3) 3
Web Resource (3) 3
Book Chapter (2) 2
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (155) 155
oncology (125) 125
index medicus (90) 90
male (82) 82
female (81) 81
middle aged (78) 78
aged (71) 71
lung neoplasms - drug therapy (68) 68
adult (64) 64
carcinoma, non-small-cell lung - drug therapy (60) 60
chemotherapy (58) 58
antineoplastic combined chemotherapy protocols - therapeutic use (54) 54
lung neoplasms - pathology (47) 47
cancer (42) 42
respiratory system (39) 39
neoplasm staging (34) 34
treatment outcome (34) 34
care and treatment (32) 32
aged, 80 and over (31) 31
carcinoma, non-small-cell lung - pathology (31) 31
lung neoplasms - mortality (30) 30
prognosis (28) 28
lung cancer (27) 27
cisplatin (26) 26
surgery (26) 26
carcinoma, non-small-cell lung - mortality (25) 25
hematology, oncology and palliative medicine (25) 25
drug therapy (24) 24
pemetrexed (24) 24
analysis (23) 23
cisplatin - administration & dosage (22) 22
non-small cell lung cancer (22) 22
survival analysis (21) 21
antineoplastic agents - therapeutic use (19) 19
cell lung-cancer (19) 19
deoxycytidine - analogs & derivatives (19) 19
guanine - analogs & derivatives (19) 19
medicine & public health (19) 19
pulmonary/respiratory (19) 19
quality of life (19) 19
gemcitabine (18) 18
lung cancer, non-small cell (18) 18
mesothelioma (18) 18
mesothelioma - drug therapy (18) 18
research (18) 18
combination (17) 17
human necessities (17) 17
hygiene (17) 17
lung neoplasms - genetics (17) 17
medical or veterinary science (17) 17
survival rate (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
clinical trials as topic (16) 16
nsclc (16) 16
survival (16) 16
follow-up studies (15) 15
phase-ii trial (15) 15
pleural neoplasms - drug therapy (15) 15
therapy (15) 15
animals (14) 14
carcinoma, non-small-cell lung - genetics (14) 14
clinical trials (14) 14
diagnosis (14) 14
lung neoplasms - therapy (14) 14
phase-iii trial (14) 14
prospective studies (14) 14
radiation therapy (14) 14
carboplatin (13) 13
deoxycytidine - administration & dosage (13) 13
disease-free survival (13) 13
medicine (13) 13
metastasis (13) 13
review (13) 13
risk factors (13) 13
bevacizumab (12) 12
carcinoma (12) 12
health aspects (12) 12
radiotherapy (12) 12
carcinoma, non-small-cell lung - therapy (11) 11
clinical-trials (11) 11
drug administration schedule (11) 11
efficacy (11) 11
glutamates - therapeutic use (11) 11
guanine - therapeutic use (11) 11
immunotherapy (11) 11
medicine, general & internal (11) 11
open-label (11) 11
phase-ii (11) 11
toxicity (11) 11
trial (11) 11
tumors (11) 11
disease progression (10) 10
gefitinib (10) 10
glutamates - administration & dosage (10) 10
guanine - administration & dosage (10) 10
management (10) 10
mesothelioma - pathology (10) 10
non-small-cell lung cancer (10) 10
patients (10) 10
quality-of-life (10) 10
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
Online Resources - Online (3) 3
Gerstein Science - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (302) 302
German (22) 22
French (10) 10
Chinese (2) 2
Korean (1) 1
Latin (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text MTE16.02 Precision Medicine in NSCLC: Lessons Learned and Perspectives
by Manegold, Christian
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S166 - S167
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology
by Manegold, Christian
Advances in Medical Sciences, ISSN 1896-1126, 09/2014, Volume 59, Issue 2, pp. 308 - 313
The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors... 
Treatment individualization | Genotype | Histotype | Advanced NSCLC | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | OPEN-LABEL | KINASE INHIBITORS | RANDOMIZED CONTROLLED-TRIAL | PHASE-III TRIAL | SUPPORTIVE CARE | CISPLATIN PLUS GEMCITABINE | FACTOR RECEPTOR MUTATIONS | 2ND-LINE TREATMENT | ELDERLY-PATIENTS | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Molecular Targeted Therapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lung Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Lung Neoplasms - therapy | Antineoplastic Agents - administration & dosage | Combined Modality Therapy - adverse effects | Evidence-Based Medicine | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - therapy | Algorithms | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Precision Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
by Martin Reck and Joachim von Pawel and Petr Zatloukal and Rodryg Ramlau and Vera Gorbounova and Vera Hirsh and Natasha Leighl and Jörg Mezger and Venice Archer and Nicola Moore and Christian Manegold
Journal of Clinical Oncology, ISSN 0732-183X, 03/2009, Volume 27, Issue 8, pp. 1227 - 1234
Purpose Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, improves survival when combined with carboplatin/paclitaxel for... 
CARBOPLATIN | LEUCOVORIN | ANGIOGENESIS | ONCOLOGY | VEGF | COMBINATION | FLUOROURACIL | REGIMENS | METASTATIC COLORECTAL-CANCER | COOPERATIVE-ONCOLOGY-GROUP | PACLITAXEL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Deoxycytidine - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Carcinoma, Non-Small-Cell Lung - mortality | Bevacizumab | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Cisplatin - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. ZD1839 (Iressa)
: a new targeted therapy for solid tumors
by Johnson, David H and Manegold, Christian
2002, The oncologist, Volume 7, suppl. 4., 39
Book
Details down arrow
5. Full Text Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
by Krug, Lee M, Dr and Kindler, Hedy L, Prof and Calvert, Hilary, MD and Manegold, Christian, Prof and Tsao, Anne S, MD and Fennell, Dean, Prof and Öhman, Ronny, MD and Plummer, Ruth, Prof and Eberhardt, Wilfried E E, MD and Fukuoka, Kazuya, MD and Gaafar, Rabab M, Prof and Lafitte, Jean-Jacques, Prof and Hillerdal, Gunnar, MD and Chu, Quincy, MD and Buikhuisen, Wieneke A, MD and Lubiniecki, Gregory M, MD and Sun, Xing, PhD and Smith, Margaret, BA and Baas, Paul, Prof and Respiratory Medicine and Allergology and Lund University and Lunds universitet and Lungmedicin och Allergologi, Lund
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 447 - 456
Summary Background Vorinostat is a histone deacetylase inhibitor that changes gene expression and protein activity. On the basis of the clinical benefit... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | HISTONE DEACETYLASE INHIBITOR | CARBOPLATIN | ORAL VORINOSTAT | THERAPY | CISPLATIN | ONCOLOGY | SUBEROYLANILIDE HYDROXAMIC ACID | II TRIAL | COMBINATION | PACLITAXEL | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Double-Blind Method | Mesothelioma - pathology | Humans | Hydroxamic Acids - adverse effects | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Lung Neoplasms - pathology | Male | Mesothelioma - drug therapy | Neoplasm Recurrence, Local - pathology | Drug-Related Side Effects and Adverse Reactions | Aged, 80 and over | Hydroxamic Acids - administration & dosage | Placebos | Adult | Female | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Mesothelioma | Gene expression | Cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
by Giorgio Vittorio Scagliotti and Purvish Parikh and Joachim von Pawel and Bonne Biesma and Johan Vansteenkiste and Christian Manegold and Piotr Serwatowski and Ulrich Gatzemeier and Raghunadharao Digumarti and Mauro Zukin and Jin S. Lee and Anders Mellemgaard and Keunchil Park and Shehkar Patil and Janusz Rolski and Tuncay Goksel and Filippo de Marinis and Lorinda Simms and Katherine P. Sugarman and David Gandara
Journal of Clinical Oncology, ISSN 0732-183X, 07/2008, Volume 26, Issue 21, pp. 3543 - 3551
Purpose Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of... 
TRIAL | 1ST-LINE TREATMENT | CARBOPLATIN | MULTICENTER | ONCOLOGY-GROUP | MESSENGER-RNA | ONCOLOGY | THYMIDYLATE SYNTHASE | MULTITARGETED ANTIFOLATE | LY231514 | PACLITAXEL | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Deoxycytidine - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Cisplatin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Glutamates - administration & dosage | Deoxycytidine - adverse effects | Female | Aged | Guanine - adverse effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Guanine - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
by Jin Soo Lee and Vera Hirsh and Keunchil Park and Shukui Qin and Cesar R. Blajman and Reury-Perng Perng and Yuh-Min Chen and Laura Emerson and Peter Langmuir and Christian Manegold
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 10, pp. 1114 - 1121
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling.... 
PLUS DOCETAXEL | GEFITINIB | ANGIOGENESIS | ONCOLOGY | FUNCTIONAL ASSESSMENT | SENSITIVITY | RESISTANCE | TUMOR-GROWTH | ZD6474 | ERLOTINIB | PREVIOUSLY TREATED PATIENTS | Smoking - adverse effects | Lung Neoplasms - drug therapy | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Odds Ratio | Double-Blind Method | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
by Nicholas J. Vogelzang and James J. Rusthoven and James Symanowski and Claude Denham and E. Kaukel and Pierre Ruffie and Ulrich Gatzemeier and Michael Boyer and Salih Emri and Christian Manegold and Clet Niyikiza and Paolo Paoletti
Journal of Clinical Oncology, ISSN 0732-183X, 07/2003, Volume 21, Issue 14, pp. 2636 - 2644
Purpose : Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously... 
TRIALS | THERAPY | ONCOLOGY | CYCLOPHOSPHAMIDE | DOXORUBICIN | MULTITARGETED ANTIFOLATE | CELL-LINES | CANCER | GEMCITABINE | LY231514 | CHEMOTHERAPY | Single-Blind Method | Multivariate Analysis | Prognosis | Glutamates - adverse effects | Mesothelioma - pathology | Guanine - analogs & derivatives | Humans | Middle Aged | Male | Mesothelioma - mortality | Reference Values | Cisplatin - administration & dosage | Pleural Neoplasms - drug therapy | Dose-Response Relationship, Drug | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Pleural Neoplasms - pathology | Drug Administration Schedule | Risk Assessment | Antineoplastic Combined Chemotherapy Protocols | Probability | Treatment Outcome | Pleural Neoplasms - mortality | Pemetrexed | Mesothelioma - drug therapy | Maximum Tolerated Dose | Survival Analysis | Cisplatin - adverse effects | Glutamates - administration & dosage | Aged | Neoplasm Staging | Guanine - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma
by Jacek Jassem and Rodryg Ramlau and Armando Santoro and Wolfgang Schuette and Assad Chemaissani and Shengyan Hong and Johannes Blatter and Susumu Adachi and Axel Hanauske and Christian Manegold
Journal of Clinical Oncology, ISSN 0732-183X, 04/2008, Volume 26, Issue 10, pp. 1698 - 1704
Purpose This multicenter, phase III study compared overall survival (OS) of second-line pemetrexed plus best supportive care (BSC) versus BSC alone in patients... 
THERAPY | CISPLATIN | ONCOLOGY | NATIONAL-CANCER-INSTITUTE | OXALIPLATIN | QUALITY-OF-LIFE | EUROPEAN-ORGANIZATION | INTERGROUP | COMBINATION | CHEMOTHERAPY | GEMCITABINE | Glutamates - therapeutic use | Mesothelioma - pathology | Guanine - analogs & derivatives | Humans | Kaplan-Meier Estimate | Mesothelioma - mortality | Treatment Outcome | Antineoplastic Agents - therapeutic use | Pleural Neoplasms - mortality | Pemetrexed | Mesothelioma - drug therapy | Pleural Neoplasms - drug therapy | Disease-Free Survival | Guanine - therapeutic use | Pleural Neoplasms - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
by Nasser Hanna and Frances A. Shepherd and Frank V. Fossella and Jose R. Pereira and Filippo De Marinis and Joachim von Pawel and Ulrich Gatzemeier and Thomas Chang Yao Tsao and Miklos Pless and Thomas Muller and Hong-Liang Lim and Christopher Desch and Klara Szondy and Radj Gervais and Shaharyar and Christian Manegold and Sofia Paul and Paolo Paoletti and Lawrence Einhorn and Paul A. Bunn Jr
Journal of Clinical Oncology, ISSN 0732-183X, 05/2004, Volume 22, Issue 9, pp. 1589 - 1597
Purpose To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated... 
ONCOLOGY | QUALITY-OF-LIFE | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Glutamates - adverse effects | Guanine - analogs & derivatives | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Taxoids - therapeutic use | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Antineoplastic Agents, Phytogenic - therapeutic use | Neutropenia - chemically induced | Guanine - therapeutic use | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Treatment Outcome | Pemetrexed | Taxoids - administration & dosage | Survival Analysis | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Guanine - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Bevacizumab for the treatment of advanced non-small-cell lung cancer
by Manegold, Christian
Expert Review of Anticancer Therapy, ISSN 1473-7140, 05/2008, Volume 8, Issue 5, pp. 689 - 699
Until recently, advances in non-small-cell lung cancer (NSCLC) care have been limited; new chemotherapy regimens have not significantly impacted patient... 
bevacizumab | antiangiogenic agents | E4599 | AVAiL | VEGF | non-small-cell lung cancer | Non-small-cell lung cancer | Antiangiogenic agents | Bevacizumab | FACTOR MONOCLONAL-ANTIBODY | ANGIOGENESIS | FACTOR EXPRESSION | PLUS CARBOPLATIN | CHEMOTHERAPY | PHASE-III TRIAL | ONCOLOGY | VEGF ANTIBODY | TUMOR-GROWTH | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - blood supply | Lung Neoplasms - mortality | Humans | Antibodies, Monoclonal - therapeutic use | Survival Rate | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Antibodies, Monoclonal, Humanized | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Lung Neoplasms - blood supply | Chemotherapy | Lung cancer, Non-small cell | Drug therapy | Methods | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
by Jan P. van Meerbeeck and Rabab Gaafar and Christian Manegold and Rob J. Van Klaveren and Eric A. Van Marck and Mark Vincent and Catherine Legrand and Andrew Bottomley and Channa Debruyne and Giuseppe Giaccone and European Organisation for Research and Treatment of Cancer Lung Cancer Group and National Cancer Institute of Canada
Journal of Clinical Oncology, ISSN 0732-183X, 10/2005, Volume 23, Issue 28, pp. 6881 - 6889
Purpose We conducted a phase III trial to determine whether first-line treatment with raltitrexed, a thymidine synthase inhibitor, and cisplatin results in... 
ONCOLOGY | EORTC | CLINICAL-TRIALS | COOPERATIVE GROUP | OXALIPLATIN | QLQ-C30 | RECIST CRITERIA | COMBINATION | GEMCITABINE | CHEMOTHERAPY | LIFE | Mesothelioma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Thiophenes - administration & dosage | Cisplatin - administration & dosage | Mesothelioma - drug therapy | Pleural Neoplasms - drug therapy | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Quinazolines - administration & dosage | Aged | Infusions, Intravenous | Neutropenia - chemically induced | Pleural Neoplasms - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
by Daphne W. Bell and Thomas J. Lynch and Sara M. Haserlat and Patricia L. Harris and Ross A. Okimoto and Brian W. Brannigan and Dennis C. Sgroi and Beth Muir and Markus J. Riemenschneider and Renee Bailey Iacona and Annetta D. Krebs and David H. Johnson and Giuseppe Giaccone and Roy S. Herbst and Christian Manegold and Masahiro Fukuoka and Mark G. Kris and José Baselga and Judith S. Ochs and Daniel A. Haber
Journal of Clinical Oncology, ISSN 0732-183X, 11/2005, Volume 23, Issue 31, pp. 8081 - 8092
Purpose Most cases of non-small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor... 
PHASE-III TRIAL | TYROSINE KINASE DOMAIN | EFFICACY | ONCOLOGY | ACQUIRED-RESISTANCE | SENSITIVITY | EGFR MUTATIONS | INHIBITOR | COMBINATION | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Gene Expression Regulation, Neoplastic | Antineoplastic Agents | Male | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Sequence Analysis, DNA | Gene Amplification | Quinazolines - therapeutic use | Biomarkers, Tumor - metabolism | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer
by Christian Manegold and Donald Gravenor and Donald Woytowitz and Jörg Mezger and Vera Hirsh and Gary Albert and Mohammed Al-Adhami and David Readett and Arthur M. Krieg and Cynthia Gail Leichman
Journal of Clinical Oncology, ISSN 0732-183X, 08/2008, Volume 26, Issue 24, pp. 3979 - 3986
Purpose This study assessed the efficacy of the combination of standard taxane plus platinum chemotherapy with the synthetic Toll-like receptor 9-activating... 
CARBOPLATIN | GEFITINIB | THERAPY | CISPLATIN | NSCLC | ONCOLOGY | OLIGONUCLEOTIDE | CPG-OLIGODEOXYNUCLEOTIDES | INHIBITOR | GEMCITABINE | PACLITAXEL | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Oligodeoxyribonucleotides - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Lung Neoplasms - pathology | Male | Toll-Like Receptor 9 - agonists | Cisplatin - administration & dosage | Carboplatin - adverse effects | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Oligodeoxyribonucleotides - adverse effects | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Paclitaxel - administration & dosage | Taxoids - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Validation for histology‐driven diagnosis in non‐small cell lung cancer using hsa‐miR‐205 and hsa‐miR‐21 expression by two different normalization strategies
by Charkiewicz, Radoslaw and Pilz, Lothar and Sulewska, Anetta and Kozlowski, Miroslaw and Niklinska, Wieslawa and Moniuszko, Marcin and Reszec, Joanna and Manegold, Christian and Niklinski, Jacek
International Journal of Cancer, ISSN 0020-7136, 02/2016, Volume 138, Issue 3, pp. 689 - 697
Targeted therapy of non‐small cell lung cancer (NSCLC) demands a more accurate tumor classification that is crucial for patient selection in personalized... 
microRNA | subclassification | non‐small cell lung cancer | target therapy | non-small cell lung cancer |